Google
LQDA — LIQUIDIA TECHNOLOGIES INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
LQDA FAQ
What is LQDA's P/E ratio?
LIQUIDIA TECHNOLOGIES INC (LQDA) currently trades at a P/E ratio of 82.49.
What is LQDA's ROE?
LIQUIDIA TECHNOLOGIES INC reports a Return on Equity (ROE) of 20.54%.
What is LQDA's dividend yield?
LIQUIDIA TECHNOLOGIES INC offers a dividend yield of 0.00%.
What is LQDA's Deepscope Quality Score?
Deepscope rates LQDA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LQDA?
Deepscope's AI Timing Score for LQDA is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LQDA belong to?
LIQUIDIA TECHNOLOGIES INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 61.85
Price
-0.69
(-1.10%)
Day Change
|
|
|---|
LQDA, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.24 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 61.85 |
| PBV / Sector |
51.22 / 2.76
|
| Earning Per Share | 0.25 |
| PE / Sector |
82.49 / 23.64
|
| PEG or PE/Growth / Sector |
3.81 / 0.13
|
| Average 1M Daily Value |
117.09 M
GREAT
|
| Average 1W Daily Value |
131.74 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:02 |
| Symbol | LQDA |
| Name | LIQUIDIA TECHNOLOGIES INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 88.93 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,561.56 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 419 Davis Drive, Morrisville, NC, United States, 27560
Phone: 919 328 4400
Website: https://www.liquidia.com
Employees: 216
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
